Drug Efficacy Biomarker GLP and non-GLP Services

Drug Efficacy Biomarker Services

Biomarker services are customized to meet the drug development demands of individual clients

- Define drug efficacy via biomarker analysis
- Evaluate drug response sooner in animal disease models and clinical studies

Nextcea integrates mass spectrometry coupled with bioinformatics to evaluate efficacy biomarkers and screen medicinal molecules based on drug efficacy responses

Biomarkers are an effective means to evaluate pharmacological response and dynamics in a quantitative manner. They are used in drug discovery and development to screen medicinal molecules, establish dose-response relationships, and achieve target effects while minimizing potential risks. Nextcea identifies early response markers in order to predict patient and animal response sooner and more non-invasively compared to traditional clinical chemistry and morphological endpoints.

Case Study: Velcade®

Nextcea identified a potential early response marker to predict the efficacy of Velcade in multiple myeloma patients[1]. The 24-hour change in serum ApoC-1 after initial dose administration correlated well with the overall clinical response after 6-weeks of treatment. Changes in serum ApoC-1 were observed much sooner compared to other response criteria.

About Nextcea, Inc.

Nextcea, Inc. is a drug development service company dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development. Nextcea integrates cross-species biomarker studies with traditional PK/PD and TK/TD. In-house platforms include HPLC/UPLC coupled to mass spectrometry LC-MS and LC-MS/MS (API-6500s and and TripleTOF 6600).

500 W. Cummings Park,#4550
Woburn, MA 01801

781-457-4010

inform@nextcea.com

English

日本語

Hirohide Mimura (三村博英):
hiro.mimura@nextcea.com

1 Hsieh F, Tengstand L, Pekol TM, et al. Elucidation of potential bortezomib response markers in multiple myeloma patients. Journal of Pharmaceutical and Biomedical Analysis 2009; 49:115-22